<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01338714</url>
  </required_header>
  <id_info>
    <org_study_id>100001-62-010</org_study_id>
    <secondary_id>100-00-62-01</secondary_id>
    <nct_id>NCT01338714</nct_id>
  </id_info>
  <brief_title>The Effect of Compound Herbal Formula (RHD-1) on HBV Carrier With Abnormal Liver Function</brief_title>
  <official_title>The Effect of Compound Herbal Formula (RHD-1) on HBV Carrier With Abnormal Liver Function: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei City Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Yang Ming University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei City Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to examine whether the compound herbal formula (RHD-1) is effective
      on HBV Carrier With Abnormal Liver Function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      % change HBV DNA title and liver function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the % change of HBV DNA title</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the % change of GPT</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Liver Dysfunction</condition>
  <arm_group>
    <arm_group_label>A foumula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compound Herbal Formula (RHD-1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B formula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dilute Compound Herbal Formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Compound Herbal Formula (RHD-1)</intervention_name>
    <description>100 ml/per day</description>
    <arm_group_label>A foumula</arm_group_label>
    <other_name>Chinese herbal medicine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dilute RHD-1</intervention_name>
    <description>100 ml/per day</description>
    <arm_group_label>B formula</arm_group_label>
    <other_name>Chinese herbal medicine dilute</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  40 &lt; GPT &lt;200 HBV carrier Age: 18-65 yrs old

        Exclusion:

        Creatinine &gt;2.0 mg/dL Total bilirubin &gt; 2.0mg/dL Not suitable patients diagnosis by
        physician in charge.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Taipei City Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Hsu CH, Hwang KC, Chiang YH, Chou P. The mushroom Agaricus blazei Murill extract normalizes liver function in patients with chronic hepatitis B. J Altern Complement Med. 2008 Apr;14(3):299-301. doi: 10.1089/acm.2006.6344.</citation>
    <PMID>18370584</PMID>
  </reference>
  <reference>
    <citation>Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002 Dec;36(6):1408-15.</citation>
    <PMID>12447866</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Taipei City Hospital</investigator_affiliation>
    <investigator_full_name>Chung-Hua Hsu</investigator_full_name>
    <investigator_title>vice president</investigator_title>
  </responsible_party>
  <keyword>HBV carrier</keyword>
  <keyword>HBV DNA title</keyword>
  <keyword>Chinese Medicine</keyword>
  <keyword>Liver function</keyword>
  <keyword>RHD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

